Label: Emperia - EMPERIA001 • Format: 4x, File MP3 320 kbps • Country: France • Genre: Electronic • Style: Hardcore
Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B Our thirty year history has made us the Self Defense/Shark Attack - Tig Notaro - Good One leader in converting injectable therapeutics into advanced oral formulations.
Utilizing our experience in Emisphere - Various - Emperia 01developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions.
Our capabilities range from early proof of concept, to extensive development and commercial capabilities. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties.
Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. We believe that these products represent tremendous promise for realizing improvements in healthcare and growth in the industry.
In the cases that such molecules are delivered by injection due to limited benefits, our technology may increase the benefit of the therapy by improving bioavailability, absorption or by decreasing time to onset of action. Gschneidner joined Emisphere in as a Medicinal Chemist and over the years has been involved in the design, synthesis, scale-up and manufacture of Emisphere carriers.
Previously, Dr. Gschneidner worked as research scientist at Cytec and as a post-doctoral fellow at the University of Colorado, Boulder. Gschneidner holds a Ph. Gschneidner has authored a number of scientific communications, including peer reviewed scientific publications and national conference presentations. He is an inventor on twenty-four U. Role in Emisphere Technologies effectively taps prior experiences to contribute solid and practical financial insight into diverse business opportunities and challenges as they arise as well as manage and maintain the day-to-day accounting Emisphere - Various - Emperia 01 of the company.
Primary work history includes, increasingly responsible domestic and international roles primarily with Merck and Co. In depth understanding of product lifecycle and portfolio management, quality assurance, sales and marketing support, finance, tax, and regulatory affairs.
Global leadership role in the creation of an operations and supply chain organization in support of the start-up and commercialization of a first of its kind living skin tissue equivalent with a 5 day shelf life.
Previous public sector role of Executive Assistant to the US Postmaster General, providing advice and guidance in the areas of business and project planning and future roles of the USPS in Emisphere - Various - Emperia 01 age of electronic mail. Ongoing academic role in partnership with the US Department of Homeland Security with regard to the responsiveness of the US healthcare supply chain in times of challenge by natural disaster or terrorist threat.
Senior advisor role with start-up consultancy focused on assessing organization maturity levels and effectiveness as is relates to value creation, readiness for change and outside in market focus.
Role in Emisphere Technologies, effectively taps historic roles in novel pharmaceutical industry start-up projects where there is a need to establish business processes, required resources, adequate organizational structure, long term supplier relationships and unwavering customer focus. Travelled extensively in the US and abroad. Nick Rothwell joined Emisphere in October of with more than 30 years experience in the pharmaceutical industry. Prior to joining Emisphere, Rothwell was the EVP of Technical Operations at Archimedes Pharma, a privately held specialty pharmaceutical company with a diverse portfolio of products.
Nick was a member of the Global Leadership Team and Heartland - The The - Infected officer of the company.
Spanning a long career, Rothwell held senior level positions of increasing responsibility with Novartis, Pharmacia and Wyeth Pharmaceuticals where he contributed to the launch of the largest vaccine in the world. Rothwell is a recognized leader in developing, implementing, and effectively managing end—to—end fully integrated supply chains and specializes in improving the overall performance across the supply network. Emisphere - Various - Emperia 01 D. Harkey Jr. Harkey obtained a B.
From to MarchEmisphere - Various - Emperia 01. Prior toMr. Prior to that, Mr. McInerney also worked in sales and marketing for Bristol-Myers Squibb. McInerney received his B. He also completed a post-graduate residency at the New York University Medical Center in drug information systems.
Mark H. Rachesky, M. Rachesky is the founder and President of MHR Fund Management LLC, an investment manager of various private investment funds that invest in inefficient market sectors, including special situation equities. Timothy G. Rothwell has been the Chairman of Emisphere Technologies Inc. Rothwell Emisphere - Various - Emperia 01 all domestic commercial operations as well as the coordination of Cielo Rojo - Lila Downs - The Very Best Of El Alma De Lila Downs Affairs and Research and Development activities in the U.
From May to SeptemberMr. From January to JanuaryMr. In his long career, Mr. He also served as the Chairman of the Pheo Para Alliance from to which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.
Weiser is currently founder and co-chairman of Actin Biomed, a New York-based healthcare investment firm advancing the discovery René* - Nathalie Simard - Tout Si Tu Maimes development of novel treatments for unmet medical needs.
Prior to founding Actin Biomed in DecemberDr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. Weiser completed his Ph. In addition, Dr. Weiser has received awards for both academic and professional excellence and is published extensively in both medical and scientific journals.
Weiser also currently serves on the board of Emisphere - Various - Emperia 01 for Ziopharm Oncology, Inc. OBManhattan Pharmaceuticals, Inc. Weiser has an M. About Us. Our development efforts are conducted internally or in collaboration with corporate development partners. Typically, the drugs that we target are at an advanced stage of development, or have already received regulatory approval, and are currently available on the market. Executive Management Team. David Gschneidner Ph.
Phil Nikolayuk Director of Finance. Louis Stamatellos, BS Ch. Nora Poliakoff Quality Management Executive. Nicholas G. Board of Directors. Director John D. Tim McInerney Director. Director Mark H. Rothwell Chairman. Rothwell Chairman Timothy G. Michael Weiser, M. Director Michael Weiser M.
Mutilation - Karneficina - Carneficina, Keep On Truckin - Donovan - Documents Serie, A Day In The Life Of... - Colonel Hathi - 170 Not Out, Simple Type (Re-mixed Version) - Kiss - Wicked Lester The Final Edition